LASER PHOTOTHERMOLYSIS PROCEDURE FOR SICKLE-CELL ERYTHROCYTES Russian patent published in 2009 - IPC A61N5/67 

FIELD: medicine.

SUBSTANCE: invention refers to development of noninvasive selective optical haemodialysis of human blood elements based on offered photothermolysis of sickle cells conjugate with negative golden nanoparticles exposed to lasing at wave length coinciding with plasmon nanoparticles resonance. Blood is introduced with golden nanoparticles and exposed to lasing at wave length coinciding with spectral maximum absorption of plasmon nanoparticles resonance and causing cell photothermolysis. Before blood is introduced with nanoparticles, their surface is negative charged comparable to membrane potential of normal erythrocytes to provide physical adhesion to plasma membrane of pathologic cells, specifically of sickle-cell erythrocytes, of nanoparticles concentration in pH neutral physiological solution with erythrocyte concentration order. Venous blood running through catheter and containing human sickle-cell erythrocytes is exposed to radiation. Herewith nanoparticles is characterised with plasmon resonance within human tissue transmission region 700-1100 nm. Laser pulse duration is to be within 10 mcs-100 ns at energy density in laser pulse not exceeding 100 mJ/cm² and laser pulse porosity at least 3. Nanoparticles represent silica nuclei in diameter 50-140 nm of silicon dioxide coated with a gold or silver of thickness within 2-20 nm, or gold or silver nanorods characterised by length to diameter ratio within 2.5 to 5 and diameter 10-40 nm.

EFFECT: selective disintegration of pathologic human blood erythrocytes not capable for oxygen migration based on selective laser photothemolysis of sickle-cell erythrocytes connected to nanoparticles during pulse lasing of blood stream in vivo.

3 cl, 6 dwg